Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 39, Issue 10, 2010, Pages 786-792

  Kämmerer, Peer W ^a   Toyoshima, Takeshi ^a,b   Eletr, Sami ^a   Kämmerer, Philipp ^a   Kuhr, Kathrin ^c   Al Nawas, Bilal ^a   Brieger, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Case control study; Oral squamous cell carcinoma; RT PCR; Single nucleotide polymorphism; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958530851     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00904.x     Document Type: Article

References (50)

1. Nather A, Sami A, Hefler L, et al. Serum levels of squamous cell carcinoma antigen as a predictor of inguinofemoral lymph node metastasis in patients with vulvar cancer. J Reprod Med 2002; 47: 718-20.
2. Neville B, Damm D, Allen C, et al. Oral and maxillofacial pathology. Philadelphia: Saunders, 2002.
3. WHO. The World Health Report - conquering suffering, enriching humanity (executive summary). Geneva: WHO, 1997.
4. Gorsky M, Littner MM, Sukman Y, et al. The prevalence of oral cancer in relation to the ethnic origin of Israeli Jews. Oral Surg Oral Med Oral Pathol 1994; 78: 408-11.
5. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
6. Jain L, V CA, D R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8: 2496-508.
7. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-5.
8. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-54.
9. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002; 24: 280-3.
10. Schneider BP, Sledge GWJ. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007; 4: 181-9.
11. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 856-62.
12. Yamaguchi T, Bando H, Mori T, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci 2007; 98: 405-10.
13. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-7.
14. Linderholm B, Tavelin B, Grankvist K, et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998; 16: 3121-8.
15. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-47.
16. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23: 193-200.
17. Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003; 64: 61-73.
18. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-14.
19. Pander J, Gelderblom H, Guchelaar HJ. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 2007; 12: 1054-60.
20. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-94.
21. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-4.
22. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46: 293-8.
23. Yapijakis C, Vairaktaris E, Vassiliou S, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 2007; 133: 787-91.
24. Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-5.
25. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003; 106: 468-71.
26. Park HM, Hong SH, Kim JW, et al. Gender-specific association of the VEGF -2578C > A polymorphism in Korean patients with colon cancer. Anticancer Res 2007; 27: 2535-9.
27. Chae YS, Kim JG, Sohn SK, et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 2006; 71: 266-72.
28. Sfar S, Hassen E, Saad H, et al. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006; 35: 21-8.
29. Ku KT, Wan L, Peng HC, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 2005; 41: 497-502.
30. Eroglu A, Gulec S, Kurtman C, et al. Vascular endothelial growth factor 936 C/T polymorphism in cancer patients. Ann Oncol 2006; 17: 1467-8.
31. Cheng CY, Chang CS, Liu CJ, et al. Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 79-84.
32. Cacev T, Loncar B, Seiwerth S, et al. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol 2008; 27: 569-74.
33. Vairaktaris E, Serefoglou Z, Avgoustidis D, et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 2009; 45: 247-53.
34. Ke Q, Liang J, Wang LN, et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog 2008; 47: 647-51.
35. Lu H, Shu XO, Cui Y, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65: 5015-9.
36. Bae SJ, Kim JW, Kang H, et al. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Res 2008; 28: 1271-6.
37. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297-302.
38. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23: 1782-90.
39. Lurje G, Zhang W, Schultheis AM, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008; 19: 1734-41.
40. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000; 89: 475-83.
41. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004; 98: 632-6.
42. Burstein HJ, Chen YH, Parker LM, et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871-7.
43. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-8.
44. Mohammadi M, Bazrafshani MR, Day PJ, et al. Vascular endothelial growth factor production is regulated by gene polymorphisms. Iran J Immunol 2009; 6: 119-29.
45. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-8.
46. Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-9.
47. Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006; 8: R22.
48. Kim JG, Chae YS, Sohn SK, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008; 14: 62-6.
49. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812-6.
50. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52: 489-99.